ANAVEX LIFE SCIENCES CORP. 8K

Anavex Life Sciences announced preliminary Q2 2026 results and a focused FDA-centric development strategy for blarcamesine in Alzheimer’s, Rett syndrome, and Fragile X, alongside Nasdaq compliance efforts and a cash runway into mid-to-late fiscal 2028.

Anavex Life Sciences Corp. reported preliminary financial results for its fiscal second quarter ended March 31, 2026 and provided a business update outlining a disciplined, data-driven strategy focused on FDA engagement to advance its lead candidate blarcamesine (ANAVEX2-73) across early Alzheimer’s disease, Rett syndrome, and Fragile X syndrome, including opening an IND for early Alzheimer’s disease in the U.S., initiating or planning key clinical pharmacology studies, aligning Phase 3 trial design for adult Rett patients, and preparing to discuss its Fragile X clinical development plan with the FDA, while noting improved quarterly net loss, a strengthened cash position expected to fund operations into mid-to-late fiscal 2028, and submission of a plan to regain compliance with Nasdaq Listing Rule 5250(c)(1).

Filing Facts

CIK

1314052

Ticker

-

Form

8K

Source Type

sec

Accession

0001731122-26-000988

Alert Tier

7